Special Issue "Natural and Tailored Enzymes for Development of Smart Biotherapeutics"
Deadline for manuscript submissions: 30 September 2021.
Interests: enzymology; enzyme engineering; therapeutic enzymes; prebiotics; enzyme-based sensors; antioxidants; enzyme-biotechnology
Interests: enzyme biotechnology; molecular enzymology; enzyme engineering; therapeutic enzymes; protein downstream processing; enzyme biosensor; enzybiotics; Algae biotechnology; cosmetics; structure-based drug design; immobilized enzyme
Aims and scope: The prospect for the pharmaceutical use of enzymes has increased greatly in the last decades. A range of specific therapeutic and pharmaceutical functions is attributed to enzymes, including anticoagulant, oncolytic, thrombolytic, anti-inflammatory, and antimicrobial properties. In addition, years now enzymes have been studied, as targets in pharmaceutical setting and almost half of the drugs, currently in clinical practice, are enzyme inhibitors. The specificity, promiscuity, plasticity and druggability are the main features that make enzymes surpass the therapeutic ability of conventional drugs. Furthermore, these biomolecules are, by nature, endowed with stimulusresponsive behavior, while protein engineering and nanotechnology are intelligent tools, allowing their redesign and customization of their therapeutic and pharmaceutical potential. Studies that focus on kinetics and catalytic mechanism of an enzyme, can unveil key factors that can be exploited for drug design and development.
The exploitation of enzymes can direct the pharmaceutical industry toward the development of novel therapeutics for the treatment of chronic, curable andperhaps incurable diseases and further stimulate their use as drug targets. The purpose of this thematic issue is to call for all pharmaceutical and biotechnological studies on natural and engineered enzymes that work as biological therapeutics or drug targets. The subtopics that will be covered within this issue include: therapeutic enzymes; rational/combinatorial engineering; enzyme replacement therapy; enzymes as antidotes; enzymes in drug delivery; enzyme prodrug therapy; enzymobiotics; enzyme-instructed self-assembly; enzyme nanocomplexes; biomimetic and artificial enzymes and structurebased design of enzyme inhibitors.
Dr. Evangelia Chronopoulou
Dr. Nikolaos Labrou
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- therapeutic enzymes
- rational/combinatorial enzyme engineering
- enzyme replacement therapy
- enzymes as antidotes
- enzymes in drug delivery
- enzyme prodrug therapy
- enzyme-instructed self-assembly
- enzyme nanocomplexes
- biomimetic and artificial enzymes
- structure-based design of enzyme inhibitors